ストックスクリーナーアプリを入手
1.67
3.73%
0.06
アフターアワーズ：
1.62
-0.05
-2.99%
Inmed Pharmaceuticals Inc (INM) 最新ニュース
InMed Pharmaceuticals Amends Deal With Mentari Therapeutics - Moomoo
InMed Pharmaceuticals (INM) Moves Forward with Merger Agreement Amendments - GuruFocus
InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4 - TradingView
InMed Pharmaceuticals (INM) Slips 1.89% as Shares Test Key Support at $1.48Counter Trend Trade - dars.gov.et
INMInMed Pharmaceuticals Inc Forecast, Target Price - Finviz
Vivo Opportunity increases InMed (INM) stake with open-market share buys - Stock Titan
InMed (INM) to merge with Mentari after $290M financing; Exchange ~2.0606 - Stock Titan
Price to sales forward of InMed Pharmaceuticals Inc. – NASDAQ:INM - TradingView
Price to earnings forward of InMed Pharmaceuticals Inc. – NASDAQ:INM - TradingView
Enterprise value to revenue forward of InMed Pharmaceuticals Inc. – NASDAQ:INM - TradingView
Penny stock InMed Pharmaceuticals merger deal targets migraine pipeline - MSN
InMed Pharmaceuticals Inc. Actuals & Estimates (NASDAQ:INM) - TradingView
InMed Pharmaceuticals Inc (INM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
InMed Pharmaceuticals Inc (INM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
InMed Pharmaceuticals Inc. Cash Flow – DUS:MWG - TradingView
Dilution adjustment of InMed Pharmaceuticals Inc. – DUS:MWG - TradingView
Current ratio of InMed Pharmaceuticals Inc. – DUS:MWG - TradingView
Total revenue of InMed Pharmaceuticals Inc. – DUS:MWG - TradingView
Basic earnings per share (basic EPS) of InMed Pharmaceuticals Inc. – DUS:MWG - TradingView
MWG Stock Price and Chart — DUS:MWG - TradingView
InMed Pharmaceuticals Inc (INM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
InMed Pharmaceuticals Inc (INM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
InMed Pharmaceuticals Inc (INM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
InMed Pharmaceuticals Inc (INM) Valuation: PE, PB & Fair Value Analysis - TradingKey
InMed Pharmaceuticals Inc (INM) Institutional Confidence - TradingKey
InMed Pharmaceuticals Inc (INM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
InMed Pharmaceuticals Inc (INM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
InMed Pharmaceuticals (INM) Slides to $1.5 as Traders Eye Support at $1.42RTH Profile - dars.gov.et
InMed-Mentari migraine merger backed by $290 million financing reshapes company strategy (INM) - MSN
InMed Pharmaceuticals Regains Nasdaq Listing Compliance Status - The Globe and Mail
Vivo Opportunity funds disclose major InMed (INM) insider share holdings - Stock Titan
Vivo Opportunity Fund Holdings Discloses Investment at InMed Pharmaceuticals with 21.7% Stake - TradingView
InMed Regains Nasdaq $1.00 Bid-Price Compliance After 10 Consecutive Business Days - TradingView
Nasdaq confirms InMed (NASDAQ: INM) back in minimum bid-price compliance - Stock Titan
InMed Pharmaceuticals (INM) Q3 2025 Earnings: Narrower Loss Reported With No Revenue StreamWeak Earnings Momentum - newsline.com
InMed Pharmaceuticals Regains Compliance With Nasdaq Continued Listing Requirements - Moomoo
InMed Pharmaceuticals (INM) Pushes Higher: Testing Resistance at $1.66 After Mild GainsDescending Triangle - newsline.com
ADAR1/Manager Daniel Schneeberger reports 24.1% stake in InMed (NASDAQ: INM) - Stock Titan
InMed Pharmaceuticals regains Nasdaq compliance - Investing.com UK
InMed Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com Australia
InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements - TMX Newsfile
Squadron Capital Management LLC Acquires 325,000 Shares in InMed Pharmaceuticals Inc - GuruFocus
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
InMed Highlights INM-901 Alzheimer’s Data in Q3 Update - TipRanks
Squadron Master Fund discloses 9.8% stake in InMed Pharmaceuticals (INM) - Stock Titan
Halper Sadeh LLC is Investigating Whether D, AVB, INM, EQR are Obtaining Fair Deals for their Shareholders - GlobeNewswire
InMed Pharmaceuticals (INM) Holds Steady Near Key Support LevelsSentiment Shift - The Legal Advocate
InMed Pharmaceuticals (INM) Holds Near Support Amid Quiet Trading SessionShort Setup Alerts - newsline.com
INM | InMed Pharmaceuticals Inc. Common Insider Trading - Quiver Quantitative
InMed Pharmaceuticals Q3 2025 Earnings: Continued Losses as Stock DeclinesTrough Earnings Signal - Newser
InMed Pharmaceuticals Q3 2025 Earnings: Net Loss Widens Amid Pipeline FocusFree Market Insights - Newser
0.15%
1.95%
大文字化:
|
ボリューム (24 時間):